AC Immune SA (ACIU) vs Vanda Pharmaceuticals (VNDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vanda Pharmaceuticals (VNDA) has outperformed AC Immune SA (ACIU) over the past year, losing 17.0% versus a loss of 27.6%. Over five years, ACIU leads with a -58.7% price change compared with -75.4% for VNDA. Vanda Pharmaceuticals is the larger company by market cap ($273.9 million vs $253.0 million), about 1.1 times the size.
On valuation, AC Immune SA trades at a lower forward P/E (4.3x vs 22.7x for Vanda Pharmaceuticals).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACIU | VNDA |
|---|---|---|
| Share price | $2.55 | $4.53 |
| Market cap | $253.04M | $273.90M |
| 1-day change | -0.20% | 0.00% |
| YTD return | -18.79% | -48.64% |
| 1-year return | -27.56% | -17.03% |
| 5-year return | -58.74% | -75.39% |
| Forward P/E | 4.28 | 22.65 |
| EPS (TTM) | $-0.54 | $-4.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.00 | $9.94 |
| 52-week low | $2.10 | $4.27 |
| Distance from 52-week high | -36.38% | -54.43% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +234.77% | +159.38% |
| Average volume | 201.86K | 974.13K |
| Shares outstanding | 99.43M | 60.46M |
| Employees | 90 | 533 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VNDA has outperformed ACIU by 10.5 percentage points over the past year.
About AC Immune SA
ACIU stock →AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 90 employees
About Vanda Pharmaceuticals
VNDA stock →Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
Health Care · Biotechnology: Pharmaceutical Preparations · 533 employees
ACIU vs VNDA FAQ
Which is bigger, AC Immune SA or Vanda Pharmaceuticals?
Vanda Pharmaceuticals (VNDA) is larger, with a market capitalization of $273.90M compared with $253.04M for AC Immune SA (ACIU).
Which stock has performed better over the past year, ACIU or VNDA?
VNDA returned -17.03% over the past 12 months, compared with -27.56% for ACIU (price return, excluding dividends). Past performance does not predict future results.
Are AC Immune SA and Vanda Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.